PetMed Express, Inc. (PETS) AI Stock Analysis

PetMed Express, Inc., founded in 1996 and based in Delray Beach, Florida, operates as a pet pharmacy serving customers throughout the United States. The company provides non-prescription medications and supplies, such as flea and tick control products, joint care solutions, vitamins, treats, nutritional supplements, and hygiene products for dogs, cats, and horses. It also supplies prescription medications, including heartworm preventatives, arthritis relief, dermatitis treatments, and diabetes medications, alongside generic alternatives. Additionally, PetMed Express retails pet essentials such as food, beds, and crates, reaching pet owners through its website, mobile app, telephone contact center, and television campaigns under the 1-800-PetMeds and PetMeds brands.

PetMed Express has experienced contracting top-line performance, with revenue falling at a 5-year CAGR of -8.8% between FY2020 and FY2026. Annual revenue dropped from $303.6M in FY2021 to $179.0M in FY2026, which represented a 34.7% decline year-over-year. Operating margin deteriorated from 10.1% in FY2021 to -17.5% in FY2026, while net margin fell from 7.9% to -32.0%. The company posted a net loss of -$57.3M and diluted EPS of -$1.31 in FY2026. For the trailing twelve months, revenue reached $168.9M with an operating margin of -15.2% and EPS of -$1.38. In the latest quarter ending June 30, 2026, quarterly revenue fell 19.9% year-over-year, while quarterly earnings grew 266.7%.

As of June 30, 2026, PetMed Express held $13.1M in cash and short-term investments against total debt of $414,000, yielding a net cash position of $12.7M. Shareholders' equity was $23.0M, and the debt-to-equity ratio was 0.02. Working capital liquidity remains constrained, indicated by a current ratio of 0.68. For FY2026, operating cash flow was -$28.4M and free cash flow stood at -$33.0M. During that fiscal year, capital expenditures totaled $4.6M, while dividends paid were $21,000. Over 5 years, the company's share count increased 6.7%.

PetMed Express trades at a market capitalization of $25.6M and an enterprise value of $20.9M. Its forward P/E ratio is 16.7x, compared to a median of 17.3x for its US-listed Healthcare peers. The stock trades at a price-to-sales multiple of 0.2x and an EV/EBITDA of 0.6x, both well below the US-listed Healthcare peer medians of 4.1x and 12.0x, respectively. Over the past year, PETS shares dropped 53.5%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock fell 95.1%, lagging the 83.0% gain of the S&P 500.

Wall Street coverage consists of 1 analyst rating, categorized as Strong Sell. The mean price target is $1.40, which implies an 18.6% increase above the last closing price of $1.18. For the current fiscal year ending March 31, 2027, the consensus estimate projects revenue of $149.2M and EPS of -$0.50. For the next fiscal year, projected revenue is $152.5M, reflecting 2.2% growth, alongside an EPS estimate of -$0.35. Over the last 4 quarters, PetMed Express recorded 0 EPS beats.

This page is an AI-written research summary of PetMed Express, Inc. (PETS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PETS income statement, PETS balance sheet, PETS key metrics, PETS analyst forecast, PETS chart. See the PETS stock overview for the latest quote and news.